Nikolayeva, Y. V.
Ulashchik, E. A.
Chekerda, E. V.
Galochkina, A. V.
Slesarchuk, N. A.
Chistov, A. A.
Nikitin, T. D.
Korshun, V. A.
Shmanai, V. V.
Ustinov, A. V.
Shtro, A. A.
Article History
Received: 13 November 2019
Revised: 25 November 2019
Accepted: 1 December 2019
First Online: 20 June 2020
COMPLIANCE WITH ETHICAL STANDARDS
: This article does not contain any research involving humans or animals as research subjects.
: The authors declare that there is no conflict of interests.
: During production of the article (December 2019–February 2020), mankind was faced with a sudden outbreak of acute respiratory illness (with significant mortality) caused by the SARS-CoV-2 enveloped coronavirus. Currently (28.02.20), COVID-19 has been recorded in many countries and is threatening to become a pandemic [21]. The unexpected emergence of the novel virus, and its rapid spread, further highlight the urgency of developing broad-spectrum antiviral therapies targeting the lipid bilayer of enveloped viruses.
Free to read: This content has been made available to all.